What is the 13F Pro Quality Score for MMED?

13F Pro ranks MiniMed Group, Inc. (MMED) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MMED's current score at https://13fpro.ai/research/MMED (free sign-up required for the full ranking).

Where does 13F Pro source MMED data?

All MiniMed Group, Inc. fundamentals and ownership data come directly from SEC EDGAR. MiniMed Group, Inc. files with the SEC under CIK 2062583. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MMED in?

MiniMed Group, Inc. (MMED) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MMED research updated on 13F Pro?

MMED's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

MiniMed Group, Inc.(MMED)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 2062583 MMED stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

MMED Stock Analysis & AI Quality Score

AI stock analysis and institutional research for MiniMed Group, Inc. (MMED), a Healthcare sector company. MMED is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (FY 2026), MiniMed Group, Inc. reports quarterly revenue of $3.1B, net income of $-333.0M, an operating margin of -6.1%. Top institutional holders of MMED by reported 13-F value include MASSACHUSETTS FINANCIAL SERVICES CO /MA/, Longaeva Partners L.P., CITADEL ADVISORS, based on the most recent SEC filings. MMED trades on the Nasdaq exchange and files with the SEC under CIK 2062583. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MMED daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MiniMed Group, Inc. directly from SEC EDGAR.

Revenue

FY 2026

$3.1B

Net Income

FY 2026

$-333.0M

Free Cash Flow

FY 2026

$-420.0M

Operating Margin

FY 2026

-6.1%

ROIC

FY 2026

-5.3%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$3.10BFY 2026

FY23 —FY26 $3.10B

Net Income

$-333.0MFY 2026

FY23 —FY26 $-333.0M

Operating Income

$-190.0MFY 2026

FY23 —FY26 $-190.0M

EPS (Diluted)

$-1.30FY 2026

FY23 —FY26 $-1.30

Total Assets

$4.63BFY 2026

FY23 —FY26 $4.63B

Op. Cash Flow

$-197.0MFY 2026

FY23 —FY26 $-197.0M

Metric	FY 2026	FY 2023
Revenue	$3.10B	—
Net Income	$-333.0M	—
Operating Income	$-190.0M	—
EPS (Diluted)	$-1.30	—
Total Assets	$4.63B	—
Operating Cash Flow	$-197.0M	—

AI Insight: MMED Financial Trends

Revenue grew 13.8% YoY to $2,265M in Q1 2026, but operating income swung to negative and cash flow deteriorated sharply.

• Revenue increased from $1,991M in Q1 2025 to $2,265M in Q1 2026, representing 13.8% YoY growth.

• Operating income fell from $2M in Q1 2025 to -$97M in Q1 2026; net income worsened to -$148M from -$41M.

• Operating cash flow turned negative at -$27M in Q1 2026, down from positive $57M in Q1 2025.

⚠ Operating profitability collapsed despite revenue growth; suggests margin compression or cost control failure.

⚠ Cash burn in latest quarter contradicts revenue momentum; working capital or restructuring charges likely warrant investigation.

AI Insight: MMED Ratio Trends

MiniMed collapsed into deep losses in Q1 2026, with operating margin plunging to -4.3% and ROIC falling to -11.2%.

• Operating margin deteriorated from 0.1% in Q1 2025 to -4.3% in Q1 2026, signaling severe operational distress.

• ROE dropped to -17.1% in Q1 2026 versus -4.7% in Q1 2025; net profit margin worsened to -6.5% from -2.1%.

• Return on assets fell to -13.6% in Q1 2026, indicating assets are now destroying shareholder value.

⚠ Data sparse after Q1 2026; only one profitable quarter (Q1 2025) in dataset. Monitor next earnings release for stabilization.

⚠ Leverage ratios unavailable across all periods; assess debt position urgently given negative returns.

Get alerted when MMED's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MiniMed Group, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MMED

MASSACHUSETTS FINANCIAL SERVICES CO /MA/
$102.6M6,878,460 sh
Longaeva Partners L.P.
$47.4M3,178,654 sh
CITADEL ADVISORS LLC
$42.5M2,851,539 sh
MILLENNIUM MANAGEMENT LLC
$38.7M2,593,434 sh
Alyeska Investment Group, L.P.
$29.8M2,000,000 sh
Sessa Capital IM, L.P.
$29.8M2,000,000 sh
Hood River Capital Management LLC
$22.5M1,505,778 sh
FMR LLC
$20.4M1,365,000 sh
Point72 Asset Management, L.P.
$17.0M1,139,793 sh
Rock Springs Capital Management LP
$15.7M1,055,000 sh

Fund	Value	Shares
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	$102.6M	6,878,460
Longaeva Partners L.P.	$47.4M	3,178,654
CITADEL ADVISORS LLC	$42.5M	2,851,539
MILLENNIUM MANAGEMENT LLC	$38.7M	2,593,434
Alyeska Investment Group, L.P.	$29.8M	2,000,000
Sessa Capital IM, L.P.	$29.8M	2,000,000
Hood River Capital Management LLC	$22.5M	1,505,778
FMR LLC	$20.4M	1,365,000
Point72 Asset Management, L.P.	$17.0M	1,139,793
Rock Springs Capital Management LP	$15.7M	1,055,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MMED on your watchlist

Track score changes the day MiniMed Group, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MMED a good stock to buy?

13F Pro's AI-powered analysis of MiniMed Group, Inc. (MMED) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MMED are available on the MMED stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MMED?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MMED. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MiniMed Group, Inc.'s investment landscape.